 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
|
||||
 |
|
||||||
 |
 |
 |
|
||||
 |
|
||||||
 |
|
||||||
 |
|
||||||
 |
|
||||||
 |
|
||||||
 |
|
||||||
 |
|
||||||
 |
|
||||||
 |
|
||||||
 |
|
||||||
 |
|
||||||
 |
|
||||||
 |
|
||||||
 |
 |
 |
|
||||
 |
|
||||||
| |
| Examples of Achievements: | |
|
Examples of Achievements (continued)
| |
|
Examples of Achievements: |
|
| (As of February 2008) |
|
| Jul. 2007 | Licensing arrangement between Sepracor Inc. of Marlborough, MA and Eisai Co., Ltd. for the the former’s LUNESTA (eszopiclone) for the treatment of insomnia in Japan. |
| Mar. 2007 | Accommodated the arrangement for VIA Pharmaceuticals, Inc. of San Francisco, CA to obtain exclusive option on preclinical leukotoriene A4 (LTA4) hydrolase inhibitors from Santen Pharmaceutical Co., Ltd. of Osaka. |
| Jul. 2006 | Licensing arrangement for Primus Pharmaceuticals, Inc. of Scottsdale, AZ to acquires the patent right from Prof. M. Yamaguchi of Shizuoka University for treatment and preventing osteoporosis. |
| Mar. 2006 | Licensing arrangement for Elixir Pharmacuticals of Cambridge, MA to acquires GLUFAST (mitiglinide), treatment for type II diabetes, from Kissei Pharmacuticals of Matsumoto. |
| Aug. 2005 | Accommodated the arrangement for Maruho Co., Ltd., Osaka to make strategic investment to Nexus Medical Partners, L.P. of Boston, MA. |
| Jul. 2005 | Accommodated an alliance between Takeda Pharmaceutical Co., Ltd., of Osaka and Santhera Pharmaceuticals AG of Switzerland for the former’s Idebenone for treatment of Friedreich’s Ataxia. |
| Jul. 2005 | Licensing arrangement between Nippon Chemiphar Co., Ltd., Tokyo and Velcura Therapeutics, Inc. of U.S. for the former’s NC-2300 and its derivatives for treatment of bone diseases. |
| Jul. 2005 | Accommodated arrangement for collaborate research agreement between Nippon Chemiphar Co., Ltd. Tokyo and Cerenis Therapeutics, Inc. of France on the former’s compounds, PPAR delta. |
| Sep. 2004 | Accommodated the arrangement for Nippon Chemiphar Co.,Ltd., Tokyo, to utilize a platform, HBTS (Human Bone Therapy System) of Velcura Therapeutics Inc. of U.S. |
| Dec. 2003 | Licensing arrangement between Photogen Therapeutics, Inc. of the U.S. and Kyosei Pharmaceuticals, a subsidiary of Sakai Chemical, Osaka for the former’s IMAGENT, ultrasound imaging agent. |
| Dec. 2003 | Accommodated arrangement for collaborate research agreement between Nippon Chemiphar Co., Ltd. Tokyo and Esperion Therapeutics of the U.S. on the former’s compounds, PPAR delta. |
| Sep. 2003 | Accommodated transferring Wyeth-Lederle Japan’s products, DIAMOX to Sanwa Kagaku, Co., Ltd.; LEDACORT and INCREMIN to Aswell Co., Ltd.; and ANDERM and VISDERM to Teikoku Seiyaku. |
| Jul. 2003 | Accommodated the arrangement for Otsuka Pharmaceutical Co. Ltd., Osaka, to utilize a platform, APP/PS1 mouse model, of MindGenix Inc. of the U.S. |
| Jul. 2003 | Accommodated the arrangement for Otsuka Pharmaceutical Co. Ltd., Osaka, to utilize a platform, APP/PS1 mouse model, of MindGenix Inc. of the U.S. |
| Jul. 2003 | Accommodated the arrangement of 2nd study for BF Research Institutes, Osaka, to utilize the platform of MindGenix Inc. |
| May. 2003 | Accommodated the arrangement of collaborative development project on second-generation product for treatment of influenza between Sankyo Co., Ltd. of Japan and Biota Holding of Australia. |
| Mar. 2003 | Accommodated arrangement for Ono Pharmaceutical Co. Ltd. Of Japan to utilize the platform of Mind Genix Inc. |
| Mar. 2003 | Licensing arrangement between Medical Information Service and Hisamitsu Pharmaceutical. Co., Ltd. for the formerﾕs Dual Syringe containing combination of lidocaine and sodium hyaluronate. |
| Mar. 2003 | Accommodated arrangement for Mitsubishi Pharma Co., Ltd. to utilize a platform of GPCR of Synaptic Pharmaceutical Corp of U.S. to validate its genes. |
| Jan. 2003 | Accommodated arrangement for BF Research Institutes, Osaka to utilize the platform of MindGenix Inc. of the U.S. |
| Mar. 2002 | Licensing arrangement between Wyeth-Lederle Japan Co., Ltd. and Meiji Seika Kaisha for the formerﾕs oral carbapenem antibiotics for Japan and Asian market.. |
| Dec. 2001 | Licensing arrangement between ISTA Pharmaceuticals,Inc. of the U.S. and Otsuka Pharmaceutical Co., Ltd. of Japan for VITRASE, an agent to treat vitreous hemorrhage. |
| Nov. 2001 | Licensing arrangement between Wyeth-Lederle Japan Co., Ltd. and Meiji Seika Kaisha for Omegacin, the formerﾕs injectable carbapenem antibiotic, for Japan market. |
| Dec. 2000 | Licensing arrangement between Photochemical Co., Ltd. of Japan and Allergan, Inc. of the U.S. for ATX-S10, the formerﾕs photodymamic therapy agent for ophthalmic use. |
| Jan. 2000 | Licensing arrangement between LTT of Japan and Hunter & Fleming of the UK to enter clinical development of LTT's OCR, an agent to treat osteoporosis. |
| Jan. 2000 | Licensing arrangement between Synaptic Pharmaceutical. Corp of the U.S and Kissei Pharmaceutical Co.,Ltd. of Japan regarding collaborative research to discover novel drug by utilizing Synapticﾕs GPCR technology. |
| Feb. 1999 | Organized and promoted "1st European Regulatory Procedures Seminar" which was held at the Shin-Takanawa Prince Hotel in Tokyo and attended by 130 people representing from 53 Japanese pharmaceutical companies |
| Apr. 1998 | Licensing arrangement between GenVec of the U.S and Asahi Chemical Co. of Japan for the latter's "TNFα gene", anti-cancer agent. |
| Jan. 1998 | The first contract between Nihon Medi-Physics Co.,Ltd. and Access Management Service for the use of the latter's PMTSP without involving capital investment. |
| Sep. 1997 | Licensing arrangement between Scotia Quanta Nova of the U.K. and Kyowa Hakko of Japan for the formerﾕs FOSCAN And agent for photodynamic therapy of cancer. |
| Mar. 1997 | Licensing arrangement between Scotia Pharmaceutical of the U.K. and Ajinomoto Co. of Japan for SC103, the formerﾕs compound for the treatment of diabetic neuropathy. |
| Apr. 1996 | Mediated the establishment of "Nisshin Kyorin Seiyaku KK", a joint venture between Nisshin Flour Milling Co., Ltd. and Kyorin Pharmaceutical Co., Ltd. |
| Apr. 1996 | Licensing arrangement between ImaRx Corp. of Arizona and Yamanouchi Pharmaceutical Co., Ltd. of Japan for the forcer's MRX115, a contrast agent for Ultrasound Imaging. |
|
Examples of Achievements (continued) | |
| Jul. 2003 | Accommodated the arrangement of 2nd study for BF Research Institutes, Osaka, to utilize the platform of MindGenix Inc. |
| May. 2003 | Accommodated the arrangement of collaborative development project on second-generation product for treatment of influenza between Sankyo Co., Ltd. of Japan and Biota Holding of Australia. |
| Mar. 2003 | Accommodated arrangement for Ono Pharmaceutical Co. Ltd., of Japan to utilize the platform of Mind Genix Inc. |
| Mar. 2003 |
Licensing arrangement between Medical Information Service and Hisamitsu Pharmaceutical. Co., Ltd. for the former’s Dual Syringe containing combination of lidocaine and sodium hyaluronate. |
| Mar. 2003 |
Accommodated arrangement for Mitsubishi Pharma Co.,Ltd. to utilize a platform of GPCR of Synaptic Pharmaceutical Corp of U.S. to validate its genes. |
| Jan. 2003 | Accommodated arrangement for BF Research Institutes, Osaka to utilize the platform of MindGenix Inc. of the U.S. |
| Mar. 2002 | Licensing arrangement between Wyeth-Lederle Japan Co., Ltd. and Meiji Seika Kaisha for the former’s L-084, oral carbapenem antibiotics for Japan and Asian market.. |
| Dec. 2001 | Licensing arrangement between ISTA Pharmaceuticals,Inc. of the U.S. and Otsuka Pharmaceutical Co., Ltd. of Japan for VITRASE, an agent to treat vitreous hemorrhage. |
| Nov. 2001 |
Licensing arrangement between Wyeth-Lederle Japan Co., Ltd. and Meiji Seika Kaisha for Omegacin, the former’s injectable carbapenem antibiotic, for Japan market. |
| Dec. 2000 | Licensing arrangement between Photochemical Co., Ltd. of Japan and Allergan, Inc. of the U.S. for ATX-S10, the former’s photodymamic therapy agent for ophthalmic use. |
| Jan. 2000 | Licensing arrangement between LTT of Japan and Hunter & Fleming of the UK to enter clinical development of LTT’s OCR, an agent to treat osteoporosis. |
| Jan. 2000 | Licensing arrangement between Synaptic Pharmaceutical. Corp of the U.S and Kissei Pharmaceutical Co.,Ltd. of Japan regarding collaborative research to discover novel drug by utilizing Synaptic’s GPCR technology. |
| Feb. 1999 |
Organized and promoted “1st European RegulatoryProcedures Seminar” which was held at the Shin-Takanawa Prince Hotel in Tokyo and attended by 130 people representing from 53 Japanese pharmaceutical companies |
| Apr. 1998 | Licensing arrangement between GenVec of the U.S and Asahi Chemical Co. of Japan for the latter’s “TNFα gene “, anti-cancer agent. |
| Jan. 1998 | The first contract between Nihon Medi-Physics Co.,Ltd. and Access Management Service for the use of the latter’s PMTSP without involving capital investment. |
| Sep. 1997 | Licensing arrangement between Scotia Quanta Nova of the U.K. and Kyowa Hakko of Japan for the former’s FOSCAN And agent for photodynamic therapy of cancer. |
| Mar. 1997 | Licensing arrangement between Scotia Pharmaceutical of the U.K. and Ajinomoto Co. of Japan for SC103, the former’s compound for the treatment of diabetic neuropathy. |
| Apr. 1996 |
Mediated the establishment of “Nisshin Kyorin Seiyaku KK”, a joint venture between Nisshin Flour Milling Co., Ltd. and Kyorin Pharmaceutical Co., Ltd. |
| Apr. 1996 | Licensing arrangement between ImaRx Corp. of Arizona and Yamanouchi Pharmaceutical Co., Ltd. of Japan for the forcer’s MRX115, a contrast agent for Ultrasound Imaging. |